Skip to content
Search

Latest Stories

Andrew Stephenson appointed as Minister Of State For Health of UK

Andrew Stephenson appointed as Minister Of State For Health of UK

He served as Lord Commissioner of the Treasury before his former role

Pendle MP Andrew Stephenson has been appointed as a Minister of State in the Department of Health and Social Care (DHSC) in the latest ministerial reshuffle.


As the new ‘Minister for Health and Secondary Care’, Stephenson would be looking after elective care recovery and screening, as well as the fight against major diseases like cancer, diabetes and stroke, as reported by Burnley Express.

The DHSC shared the news on X (formerly Twitter) on 14 November, it read:

“Helping NHS services recover from the legacy of the pandemic, whilst dealing with winter pressures and the challenges of inflation will not be easy, but it is a challenge I am looking forward to,” Stephenson told Burnley Express.

“I am also keen to ensure that significant manifesto commitments, such as the pledge to deliver 50,000 nurses and 40 new hospitals remain on track. Especially as one of those 40 new hospitals is Airedale, which is used by so many Colne and West Craven residents,” he added.

Stephenson has served as Lord Commissioner of the HM Treasury from 27 October 2022 to 13 November 2023.

Before that, he was Parliamentary Under Secretary of State at the Department for Levelling Up, Housing and Communities from 20th September 2022 to 27th October 2022, and was Minister without Portfolio at the Cabinet Office between 7 July 2022 and 6 September 2022.

He has previously served as the Minister of State at the Department for Transport from 13 February 2020 to July 2022, and Minister of State at the Foreign and Commonwealth Office and the Department for International Development from 25 July 2019 to 13 February 2020.

He was appointed as Parliamentary Under Secretary of State at the Department for Business, Energy and Industrial Strategy on 4 April 2019 and served it till 25 July 2019.

He was also a Lord Commissioner of the treasury from January 2018 to April 2019 and served as an Assistant Government Whip from June 2017 to January 2018.

Stephenson was first elected as Conservative MP for Pendle in May 2010.

More For You

How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Support for generic medicines manufacturers key to affordable healthcare- Teva UK director

Teva UK sounds alarm on accelerating consolidation of critical generic medicines

Photo credit: gettyimages

Exclusive: Teva UK calls for inclusion of generic manufacturers in policy talks

A healthy and vibrant generics marketplace supports not only patients but also contributes billions of pounds in savings to the drugs bill. However, growing pressures on generic medicine manufacturers could threaten this vital part of the healthcare ecosystem, warns Ryan Ruscoe, senior director of generics and OTC at Teva UK.

Speaking exclusively to Pharmacy Business, Ruscoe stressed the urgent need to address supply chain vulnerabilities, particularly for critical generic medicines.

Keep ReadingShow less